These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1347220)

  • 21. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases.
    Hozumi I; Hasegawa T; Honda A; Ozawa K; Hayashi Y; Hashimoto K; Yamada M; Koumura A; Sakurai T; Kimura A; Tanaka Y; Satoh M; Inuzuka T
    J Neurol Sci; 2011 Apr; 303(1-2):95-9. PubMed ID: 21292280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients.
    Nagata T; Nagano I; Shiote M; Narai H; Murakami T; Hayashi T; Shoji M; Abe K
    Neurol Res; 2007 Dec; 29(8):772-6. PubMed ID: 17672928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease. The possible relationship of laterality to dementia and neurochemical findings.
    Direnfeld LK; Albert ML; Volicer L; Langlais PJ; Marquis J; Kaplan E
    Arch Neurol; 1984 Sep; 41(9):935-41. PubMed ID: 6477229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Rentzos M; Zoga M; Paraskevas GP; Kapaki E; Rombos A; Nikolaou C; Tsoutsou A; Vassilopoulos D
    J Geriatr Psychiatry Neurol; 2006 Jun; 19(2):114-7. PubMed ID: 16690997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kawakatsu S; Morinobu S; Shinohara M; Totsuka S; Kobashi K
    Biol Psychiatry; 1990 Sep; 28(5):387-400. PubMed ID: 1698467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects.
    Wuolikainen A; Jonsson P; Ahnlund M; Antti H; Marklund SL; Moritz T; Forsgren L; Andersen PM; Trupp M
    Mol Biosyst; 2016 Apr; 12(4):1287-98. PubMed ID: 26883206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis.
    Steinacker P; Fang L; Kuhle J; Petzold A; Tumani H; Ludolph AC; Otto M; Brettschneider J
    PLoS One; 2011; 6(8):e23600. PubMed ID: 21858182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease.
    Jolkkonen JT; Soininen HS; Riekkinen PJ
    J Neurol Sci; 1987 Feb; 77(2-3):153-9. PubMed ID: 2950209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF somatostatin-like immunoreactivity in dementia.
    Beal MF; Growdon JH; Mazurek MF; Martin JB
    Neurology; 1986 Feb; 36(2):294-7. PubMed ID: 2868429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal Fluid Profiles in Parkinson's Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment.
    Niimi Y; Mizutani Y; Akiyama H; Watanabe H; Shiroki R; Hirabayashi Y; Hoshinaga K; Mutoh T
    J Parkinsons Dis; 2021; 11(1):221-232. PubMed ID: 33216044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
    Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
    J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
    Blennow K; Biscetti L; Eusebi P; Parnetti L
    Mov Disord; 2016 Jun; 31(6):836-47. PubMed ID: 27145480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
    Cheng FC; Kuo JS; Chia LG; Dryhurst G
    J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A correlation study of CSF neuropeptides in Alzheimer's and Parkinson's disease.
    Jolkkonen J; Hartikainen P; Soikkeli R; Bissette G; Nemeroff C; Riekkinen P
    Neuropeptides; 1991 Jun; 19(2):97-102. PubMed ID: 1682848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic activity of serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients against acetylcholinesterase.
    Niebrój-Dobosz I; Domitrz I; Mickielewicz A
    Folia Neuropathol; 1999; 37(2):107-12. PubMed ID: 10464429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease.
    Sjödin S; Brinkmalm G; Öhrfelt A; Parnetti L; Paciotti S; Hansson O; Hardy J; Blennow K; Zetterberg H; Brinkmalm A
    Alzheimers Res Ther; 2019 Sep; 11(1):82. PubMed ID: 31521194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid "specific" proteins in various degenerative neurological diseases.
    Wikkelsø C; Blomstrand C
    Acta Neurol Scand; 1982 Aug; 66(2):199-208. PubMed ID: 6215816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.